News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
379,919 Results
Type
Article (26801)
Company Profile (163)
Press Release (352953)
Multimedia
Podcasts (97)
Webinars (14)
Section
Business (94526)
Career Advice (830)
Deals (17833)
Drug Delivery (122)
Drug Development (48171)
Employer Resources (63)
FDA (10834)
Job Trends (8558)
News (175897)
Policy (21168)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (2)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (5)
Academia (1927)
Academic (1)
Accelerated approval (47)
Adcomms (34)
Allergies (136)
Alliances (26253)
ALS (167)
Alzheimer's disease (1099)
Antibody-drug conjugate (ADC) (300)
Approvals (11085)
Artificial intelligence (473)
Autoimmune disease (207)
Automation (32)
Bankruptcy (117)
Best Places to Work (7752)
BIOSECURE Act (15)
Biosimilars (193)
Biotechnology (116)
Bladder cancer (159)
Brain cancer (40)
Breast cancer (516)
Cancer (4131)
Cardiovascular disease (388)
Career advice (730)
Career pathing (21)
CAR-T (225)
CDC (58)
Celiac Disease (1)
Cell therapy (670)
Cervical cancer (28)
Clinical research (43179)
Collaboration (1479)
Company closure (3)
Compensation (612)
Complete response letters (87)
COVID-19 (1816)
CRISPR (99)
C-suite (773)
Cystic fibrosis (124)
Data (6054)
Decentralized trials (1)
Denatured (26)
Depression (122)
Dermatology (59)
Diabetes (425)
Diagnostics (3789)
Digital health (39)
Diversity (9)
Diversity, equity & inclusion (16)
Drug discovery (243)
Drug pricing (173)
Drug shortages (31)
Duchenne muscular dystrophy (218)
Earnings (36593)
Editorial (58)
Employer branding (6)
Employer resources (61)
Events (56014)
Executive appointments (681)
FDA (13594)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (13)
Frontotemporal dementia (26)
Funding (1091)
Gene editing (199)
Generative AI (43)
Gene therapy (605)
GLP-1 (770)
Government (3873)
Grass and pollen (7)
Guidances (272)
Healthcare (11347)
HIV (63)
Huntington's disease (46)
IgA nephropathy (83)
Immunology and inflammation (160)
Immuno-oncology (77)
Indications (145)
Infectious disease (2066)
Inflammatory bowel disease (174)
Inflation Reduction Act (7)
Influenza (89)
Intellectual property (161)
Interviews (141)
IPO (9786)
IRA (34)
Job creations (1214)
Job search strategy (615)
JPM (40)
Kidney cancer (17)
Labor market (42)
Layoffs (280)
Leadership (23)
Legal (3745)
Liver cancer (64)
Longevity (18)
Lung cancer (593)
Lymphoma (345)
Machine learning (40)
Management (22)
Manufacturing (718)
MASH (147)
Medical device (6161)
Medtech (6221)
Mergers & acquisitions (8909)
Metabolic disorders (1116)
mRNA (147)
Multiple sclerosis (146)
NASH (20)
Neurodegenerative disease (289)
Neuropsychiatric disorders (69)
Neuroscience (2248)
NextGen: Class of 2026 (3302)
Non-profit (2398)
Now hiring (22)
Obesity (542)
Opinion (182)
Ovarian cancer (147)
Pain (183)
Pancreatic cancer (201)
Parkinson's disease (276)
Partnered (16)
Patents (358)
Patient recruitment (437)
Peanut (46)
People (31771)
Pharmaceutical (37)
Pharmacy benefit managers (20)
Phase 1 (12290)
Phase 2 (18156)
Phase 3 (16120)
Pipeline (6352)
Policy (288)
Postmarket research (1782)
Preclinical (4911)
Press Release (21)
Prostate cancer (239)
Psychedelics (40)
Radiopharmaceuticals (246)
Rare diseases (855)
Real estate (2707)
Recruiting (27)
Regulatory (17902)
Reports (25)
Research institute (1713)
Resumes & cover letters (122)
Rett syndrome (35)
RNA editing (16)
RSV (62)
Schizophrenia (129)
Series A (186)
Series B (142)
Service/supplier (1)
Sickle cell disease (94)
Special edition (16)
Spinal muscular atrophy (119)
Sponsored (28)
Startups (1848)
Stomach cancer (13)
Supply chain (84)
Tariffs (80)
The Weekly (69)
Vaccines (804)
Venture capital (85)
Weight loss (364)
Women's health (76)
Worklife (6)
Date
Today (107)
Last 7 days (506)
Last 30 days (2215)
Last 365 days (19893)
2026 (9313)
2025 (19465)
2024 (21738)
2023 (24208)
2022 (31904)
2021 (34681)
2020 (32645)
2019 (27269)
2018 (20074)
2017 (18583)
2016 (16927)
2015 (19274)
2014 (14120)
2013 (11973)
2012 (12727)
2011 (13040)
2010 (10438)
Location
Africa (450)
Alabama (42)
Alaska (2)
Arizona (116)
Arkansas (6)
Asia (25115)
Australia (3677)
California (7744)
Canada (2266)
China (981)
Colorado (294)
Connecticut (374)
Delaware (326)
Europe (64271)
Florida (1101)
Georgia (274)
Hawaii (1)
Idaho (29)
Illinois (675)
India (62)
Indiana (444)
Iowa (9)
Japan (454)
Kansas (78)
Kentucky (17)
Louisiana (25)
Maine (32)
Maryland (1054)
Massachusetts (6092)
Michigan (134)
Minnesota (305)
Mississippi (1)
Missouri (91)
Montana (17)
Nebraska (13)
Nevada (71)
New Hampshire (28)
New Jersey (2606)
New Mexico (15)
New York (2327)
North Carolina (1026)
North Dakota (7)
Northern California (4052)
Ohio (269)
Oklahoma (9)
Oregon (29)
Pennsylvania (1615)
Puerto Rico (14)
Rhode Island (30)
South America (577)
South Carolina (37)
Southern California (2959)
Tennessee (90)
Texas (1207)
United States (28847)
Utah (234)
Vermont (1)
Virginia (239)
Washington D.C. (48)
Washington State (678)
West Virginia (1)
Wisconsin (82)
Wyoming (2)
379,919 Results for "european medicines agency ema".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
March 30, 2026
·
5 min read
Press Releases
Ray Therapeutics Granted Priority Medicines (PRIME) Designation from the European Medicines Agency for RTx-015 in Retinitis Pigmentosa
April 29, 2026
·
3 min read
Press Releases
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
May 21, 2026
·
7 min read
Press Releases
Neurona Therapeutics Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to NRTX-1001 in the Treatment of Drug-Resistant Focal Epilepsy
November 5, 2025
·
4 min read
Press Releases
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
December 29, 2025
·
10 min read
Press Releases
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
March 10, 2026
·
7 min read
Press Releases
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
March 31, 2026
·
9 min read
Press Releases
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
October 20, 2025
·
5 min read
Press Releases
IntraBio Receives Positive European Medicines Agency Opinion for Orphan Medicinal Product Designation for Acetylleucine for CACNA1A Disorders
February 25, 2026
·
2 min read
Press Releases
AOB Pharma receives European Medicines Agency (EMA) positive decision on the pediatric investigation plan (PIP), supporting future development of B244 for the treatment of mild to moderate atopic dermatitis in children, adolescents, and adults in the European Union (EU)
December 3, 2025
·
5 min read
1 of 37,992
Next
